Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience, health risks, and extreme weather.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts degree in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Many addicts inherit a brain that has trouble just saying no to drugs.

A study in Science finds that cocaine addicts have abnormalities in areas of the brain involved in self-control. And these abnormalities appear to predate any drug abuse.

The study, done by a team at the University of Cambridge in the U.K., looked at 50 pairs of siblings. One member of each pair was a cocaine addict. The other had no history of drug abuse.

A club drug called "Special K" is generating a lot of buzz among researchers who study depression.

That's because "Special K," which is actually an FDA-approved anesthetic named ketamine, can relieve even suicidal depression in a matter of hours. And it works on many patients who haven't responded to current antidepressants like Prozac.

Those traditional drugs, which act on the brain's serotonin system, can take more than a month to kick in, and don't work for up to 40 percent of people with major depression.

There's no quick fix for severe depression.

Although antidepressants like Prozac have been around since the 1970s, they usually take weeks to make a difference. And for up to 40 percent of patients, they simply don't work.

As a result, there are limited options when patients show up in an emergency room with suicidal depression.

The doctors and nurses at Ben Taub General Hospital in Houston say they see this problem every day.

The more exposure children have to chemicals called perfluorinated compounds, the less likely they are to have a good immune response to vaccinations, a study just published in JAMA, the Journal of the American Medical Association shows.

The finding suggests, but doesn't prove, that these chemicals can affect the immune system enough to make some children more vulnerable to infectious diseases.

You may want to read this twice if you're older than 45. In fact, you may have to.

That's because your mental abilities are already in decline, according to a study of 7,390 British civil servants just published in BMJ, the British Medical Journal.

Pages